ClearPath Diagnostics, a physician-owned pathology and cytology laboratory located in Syracuse, says it’s the first laboratory in upstate New York to perform the Cervista HPV HR test. It screens for the presence of high-risk types of the human papillomavirous, which is strongly associated with the development of cervical cancer. FDA-approved Cervista HPV HR is the first new screening test for high-risk HPV in more than a decade, ClearPath says.
The Cervista HPV HR test is used in combination with Pap testing, sharing the same cervical specimen and detects the presence of 14 high-risk HPV types.
Michael A. Jozefczyk, M.D., president of ClearPath Diagnostics, said in a news release that Cervista is the first high-risk HPV assay that includes a quality control check, which will greatly reduce the number of false-positive results.
ClearPath Diagnostics is also bringing Cervista to the Southern Tier. The company now has a client-service representative in the Binghamton area to serve physicians and the patients they serve.
ClearPath’s pathologist owners are Drs. Josefczyk, Michael Mazur, and Kenneth Strumpf.